Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) fell 19.7% during trading on Wednesday . The stock traded as low as C$2.15 and last traded at C$2.16. 61,248 shares changed hands during trading, a decline of 57% from the average session volume of 141,811 shares. The stock had previously closed at C$2.69.
Cardiol Therapeutics Stock Performance
The firm has a 50-day simple moving average of C$2.77 and a two-hundred day simple moving average of C$2.83. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39. The company has a market capitalization of C$176.80 million, a price-to-earnings ratio of -5.75 and a beta of 0.70.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
